US FDA initiative to encourage regulatory DIY among firms
This article was originally published in Clinica
Executive Summary
The US Food and Drug Administration is working on a pilot program that will allow medical device companies to self-identify and correct possible regulatory violations instead of undergoing FDA inspections.